Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study.
John Leonard
Consultant or Advisory Role - Gilead Sciences
Nina D. Wagner-Johnston
No relevant relationships to disclose
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Marshall T. Schreeder
Research Funding - Gilead Sciences
Nathan Hale Fowler
Research Funding - Gilead Sciences
Jeff Porter Sharman
Research Funding - Gilead Sciences
Ralph V. Boccia
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Kanti Roop Rai
Research Funding - Gilead Sciences
Thomas E. Boyd
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Yeonhee Kim
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences